

ALLERGAN INC
Form 8-K
January 22, 2002

Table of Contents

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

January 22, 2002 (January 22, 2002)
Date of Report (Date of earliest event reported)

ALLERGAN, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation) (Commission File
Number) (IRS Employer
Identification No.) **2525 Dupont Drive**
Irvine, California
92612(Address of Principal
Executive Offices) (Zip Code)

1-10269

95-1622442

(714) 246-4500
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

TABLE OF CONTENTS

Item 5. Other Events.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

SIGNATURES

EXHIBIT 99.1

Table of Contents

Item 5. Other Events.

On January 22, 2002, Allergan, Inc., announced its intention to separate its ophthalmic surgical and contact lens care business lines into an independent publicly traded company through a tax-free distribution to Allergan shareholders. The press release dated January 22, 2002 announcing this transaction is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

99.1 Press release of Registrant dated January 22, 2002.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLERGAN, INC.

Date:
January 22,
2002 By: /S/
DOUGLAS S.
INGRAM

Douglas S.
Ingram
Corporate Vice
President,
General
Counsel and
Secretary

Table of Contents

EXHIBIT INDEX

Exhibit Number	Exhibit Description
99.1	Press release of Registrant dated January 22, 2002.